0000899243-23-014998.txt : 20230608 0000899243-23-014998.hdr.sgml : 20230608 20230608211528 ACCESSION NUMBER: 0000899243-23-014998 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230403 FILED AS OF DATE: 20230608 DATE AS OF CHANGE: 20230608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH IAN F CENTRAL INDEX KEY: 0001197032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38360 FILM NUMBER: 231003649 MAIL ADDRESS: STREET 1: C/O ACORDA THERAPEUTICS, INC. STREET 2: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Solid Biosciences Inc. CENTRAL INDEX KEY: 0001707502 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 900943402 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 RUTHERFORD AVENUE STREET 2: 3RD FLOOR CITY: CHARLESTOWN STATE: MA ZIP: 02129 BUSINESS PHONE: 617-337-4680 MAIL ADDRESS: STREET 1: 500 RUTHERFORD AVENUE STREET 2: 3RD FLOOR CITY: CHARLESTOWN STATE: MA ZIP: 02129 FORMER COMPANY: FORMER CONFORMED NAME: Solid Biosciences, LLC DATE OF NAME CHANGE: 20170524 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-03 0 0001707502 Solid Biosciences Inc. SLDB 0001197032 SMITH IAN F C/O SOLID BIOSCIENCES INC. 500 RUTHERFORD AVENUE CHARLESTOWN MA 02129 1 0 0 0 0 Common Stock 2023-04-03 4 M 0 15569 A 53239 D Restricted Stock Units 2023-04-03 4 M 0 15569 0.00 D Common Stock 15569 46709 D Director Stock Option (Right to Buy) 6.37 2023-06-06 4 A 0 9650 0.00 A 2033-06-06 Common Stock 9650 9650 D Restricted stock units convert into common stock on a one-for-one basis. The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. /s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith 2023-06-08